Jon Faiz Kayyem is VP at GenMark Diagnostics, Inc. (GNMK). They have made 50 open-market trades across 4 companies since 2008, most recently 2026-09-23.
CIK 0001366268
14 open-market purchases totalling $18.7M since 2008, against 36 sales. Across 11 scored buys the stock is up 1.6% at ninety days, and 0.6 points ahead of the S&P over the same stretch.
14 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| RPRX | 4,292,136 | $261.7M |
| INBX | 434,360 | $38.7M |
| GNMK | 197,622 | $4.8M |
| BDSX | 180,085 | $4.2M |
| INXB | 6,250 | — |
| Total | $309.4M |
Shares reported on the most recent Form 4, priced at the 2026-09-23 close. 1 holding could not be priced and is excluded from the total.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 29% | 67% | 73% |
| Avg Move | -0.1% | -5.1% | +1.6% |
| Alpha | -14.8% | -5.8% | +0.6% |
| Scored | 14 | 12 | 11 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| INBX | BUY | 2026-09-23 | 2026-09-23 | $100.00 | $500K | -7.5% | — | — |
| INBX | BUY | 2026-09-16 | 2026-09-17 | $100.00 | $500K | -1.3% | — | — |
| INBX | BUY | 2026-09-08 | 2026-09-08 | $113.52 | $568K | -7.8% | -22.5% | — |
| INBX | BUY | 2024-11-19 | 2024-11-22 | $14.22 | $1.5M | -2.6% | -6.6% | -17.4% |
| INBX | BUY | 2024-06-05 | 2024-06-07 | $17.32 | $2.0M | -16.1% | -21.2% | -7.2% |
| INBX | BUY | 2024-05-31 | 2024-06-04 | $17.18 | $9.9M | -14.3% | -29.7% | -13.0% |
| INBX | SELL | 2023-01-23 | 2023-01-23 | $25.26 | $480K | +28.1% | +7.1% | +7.1% |
| INBX | SELL | 2022-12-21 | 2022-12-22 | $27.02 | $513K | +28.1% | +7.1% | +7.1% |
| INBX | SELL | 2022-11-21 | 2022-11-22 | $29.89 | $568K | +28.1% | +7.1% | +7.1% |
| BDSX | BUY | 2022-11-21 | 2022-11-21 | $1.15 | $400K | -0.6% | +13.6% | +49.4% |
| INBX | SELL | 2022-10-21 | 2022-10-24 | $30.13 | $573K | +28.1% | +7.1% | +7.1% |
| GNMK | SELL | 2018-02-02 | 2018-02-06 | $5.13 | $759 | -11.8% | -10.0% | +42.8% |
| GNMK | SELL | 2017-12-04 | 2017-12-06 | $4.70 | $635 | -0.2% | +18.6% | +13.0% |
| GNMK | SELL | 2017-11-20 | 2017-11-21 | $4.74 | $6K | -4.6% | -2.7% | -7.4% |
| GNMK | SELL | 2017-11-02 | 2017-11-03 | $7.24 | $977 | +11.5% | +3.7% | +19.0% |
| GNMK | SELL | 2017-09-05 | 2017-09-06 | $9.75 | $1K | +2.9% | +3.8% | -52.7% |
| GNMK | SELL | 2017-08-21 | 2017-08-23 | $9.45 | $12K | -0.7% | +0.1% | -50.5% |
| GNMK | SELL | 2017-08-02 | 2017-08-04 | $10.33 | $1K | -10.8% | -14.0% | -33.9% |
| GNMK | SELL | 2017-06-02 | 2017-06-05 | $12.89 | $2K | -5.0% | -7.2% | -25.4% |
| GNMK | SELL | 2017-05-19 | 2017-05-23 | $12.89 | $16K | -3.1% | -3.4% | -27.2% |
| GNMK | SELL | 2017-05-02 | 2017-05-04 | $13.34 | $2K | +6.4% | +0.5% | -14.0% |
| GNMK | SELL | 2017-03-07 | 2017-03-09 | $12.18 | $4K | +6.1% | +5.4% | +4.7% |
| GNMK | SELL | 2017-03-03 | 2017-03-03 | $12.29 | $2K | -0.9% | +7.3% | +4.5% |
| GNMK | SELL | 2017-02-21 | 2017-02-21 | $10.08 | $53K | +18.6% | +25.9% | +26.5% |
| GNMK | SELL | 2017-02-02 | 2017-02-03 | $11.58 | $2K | -2.9% | +8.0% | +11.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.